Eckert & Ziegler Vitalea Science, or EZVS, and BioCore Co. Ltd. have announced the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry.
BioCore, the first bioanalytical CRO in Korea, has an established reputation for quality service and a customer base that extends throughout Asia. This relationship expands BioCore's portfolio, adding EZVS's Accelerator Mass Spectrometry (AMS) based services to their suite of advanced offerings, and facilitates EZVS's entry into the growing Asian pharmaceutical market.
AMS is an ultrasensitive radiocarbon detection platform that complements other tools available to the pharmaceutical scientist. "Atom counting" sensitivity enable new avenues of clinical drug development in ways that were not previously possible.
BioCore President and CEO Hyung Sik Choie comments, "This alliance brings capabilities through the BioCore interface with immediate benefit to the Korean pharmaceutical community by reducing the timeline to bring new drugs to market."
These studies, while approved under FDA and ICH guidances, are not currently being performed in Korea due to the lack of bio accelerator expertise.
EZVS's team of experts includes the founders of applied AMS methods for biological determinations and innovators of next generation Bio MICADAS AMS technology.
Dr Stephen Dueker, EZVS CSO, stated, "We are very pleased to be represented by BioCore. Alignment with the foremost CRO in Korea provides EZVS presence in Asia and strengthens our credibility as we introduce the benefits of applied AMS into new territory."
The agreement combines the technical expertise of both companies to deliver solutions designed to streamline the drug development process and accelerate commercialization to pharmaceutical sponsors.